DOTA-Pep-1L (TFA)

DOTA-Pep-1L TFA is a peptide conjugated with DOTA and Pep-1L, a peptide that specifically targets the IL13RA2 receptor. DOTA-Pep-1L TFA can be used for PET imaging and tumor-targeted therapy research[1].

12352100

Interleukin Related

Immunology/Inflammation

Cancer-programmed cell death

Cancer

98.60

O=C(N[C@@H](CS)C(NCC(N[C@@H](CCC(O)=O)C(N[C@@H](CCSC)C(NCC(N[C@@H](CC1=CNC2=CC=CC=C12)C(N[C@@H](C(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CS)C(NCC(NCC(NCC(N[C@@H](CO)C(NCCCCCC(N[C@@H](CCCCN)C(N[C@@H](CCCCNC(CN3CCN(CCN(CCN(CC3)CC(O)=O)CC(O)=O)CC(O)=O)=O)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](C)N.OC(C(F)(F)F)=O.[x]

C88H146N28O27S3.xC2HF3O2

2124.47 (free base)

[1]Sattiraju A, et al. IL13RA2 targeted alpha particle therapy against glioblastomas. Oncotarget. 2017 Jun 27;8 (26) :42997-43007.

Blue Ice

-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)

http://file.medchemexpress.com/batch_PDF/HY-P11287A/DOTA-Pep-1L-TFA-SDS-MedChemExpress.pdf

Peptides

No Development Reported